| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $32,493 | 3 | 100 |
Sells | $0 | 0 | 0 |
| Doyle John Brendan | Chief Financial Officer | 1 | $11,300 | 0 | $0 | $11,300 |
| Caggiano Anthony | Chief Medical Officer | 1 | $11,100 | 0 | $0 | $11,100 |
| Ricciardi Lisa | CEO & President | 1 | $10,093 | 0 | $0 | $10,093 |
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's …
Over the last 12 months, insiders at Cognition Therapeutics, Inc. have bought $32,493 and sold $0 worth of Cognition Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cognition Therapeutics, Inc. have bought $1M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Doyle John Brendan (Chief Financial Officer) — $11,300. Caggiano Anthony (Chief Medical Officer) — $11,100. Ricciardi Lisa (CEO & President) — $10,093.
The last purchase of 9,175 shares for transaction amount of $10,093 was made by Ricciardi Lisa (CEO & President) on 2026‑04‑16.
| 2026-04-16 | Ricciardi Lisa | CEO & President | 9,175 0.0124% | $1.10 | $10,093 | -6.76% | ||
| 2026-04-16 | Caggiano Anthony | Chief Medical Officer | 10,000 0.0136% | $1.11 | $11,100 | -6.76% | ||
| 2026-04-16 | Doyle John Brendan | Chief Financial Officer | 10,000 0.0138% | $1.13 | $11,300 | -6.76% | ||
| 2025-01-31 | Ricciardi Lisa | CEO & President | 38,851 0.094% | $0.77 | $30,001 | +1.69% | ||
| 2024-03-14 | Ricciardi Lisa | CEO & President | 5,700 0.0172% | $1.75 | $9,975 | -60.21% | ||
| 2022-11-29 | RICHSTONE ELLEN B | director | 10,000 0.0453% | $2.65 | $26,550 | -29.84% | ||
| 2022-11-28 | Kreis Leslie W. | director | 16,064 0.0706% | $2.65 | $42,565 | -31.76% | ||
| 2022-11-28 | Fletcher Aaron G.L. | director | 16,064 0.0706% | $2.65 | $42,565 | -31.76% | ||
| 2022-11-16 | Kreis Leslie W. | director | 71,000 0.3069% | $1.40 | $99,400 | +27.74% | ||
| 2022-11-16 | Fletcher Aaron G.L. | director | 71,000 0.3069% | $1.40 | $99,400 | +27.74% | ||
| 2022-11-15 | Kreis Leslie W. | director | 1.5M 5.2511% | $1.20 | $1.8M | +20.69% | ||
| 2022-11-15 | Fletcher Aaron G.L. | director | 1.5M 5.2511% | $1.20 | $1.8M | +20.69% | ||
| 2022-11-15 | Wallace Peggy | director | 12,500 0.0438% | $1.20 | $15,000 | +20.69% | ||
| 2022-11-15 | Ricciardi Lisa | CEO & President | 12,000 0.0455% | $1.30 | $15,600 | +20.69% | ||
| 2021-10-13 | Sale | Ogden CAP Associates, LLC | 10 percent owner | 74.05 0.0014% | $12.00 | $889 | -76.39% | |
| 2021-10-13 | Sale | Golden Seeds Cognition Therapeutics LLC | 10 percent owner | 33.09 0.0006% | $12.00 | $397 | -76.39% | |
| 2021-10-13 | Sale | Breedlove Mark H. | director | 23.48 0.0004% | $12.00 | $282 | -76.39% | |
| 2021-10-13 | Sale | Fletcher Aaron G.L. | director | 180.56 0.0034% | $12.00 | $2,167 | -76.39% | |
| 2021-10-13 | Sale | BIOS Memory SPV I, LP | 10 percent owner | 90.28 0.0017% | $12.00 | $1,083 | -76.39% | |
| 2021-10-13 | Fletcher Aaron G.L. | director | 380,000 7.2005% | $12.00 | $4.56M | -76.39% |
| Ricciardi Lisa | CEO & President | 1715851 1.8044% | $1.2M | 5 | 0 | <0.0001% |
| Caggiano Anthony | Chief Medical Officer | 874906 0.92% | $611,996.75 | 1 | 0 | |
| Doyle John Brendan | Chief Financial Officer | 627509 0.6599% | $438,942.55 | 1 | 0 | |
| Fletcher Aaron G.L. | director | 2021906 2.1262% | $1.41M | 4 | 1 | <0.0001% |
| Kreis Leslie W. | director | 2021906 2.1262% | $1.41M | 3 | 0 | +5.55% |
| BIOS Memory SPV I, LP | 10 percent owner | 899905 0.9463% | $629,483.55 | 1 | 1 | <0.0001% |
| Wallace Peggy | director | 37961 0.0399% | $26,553.72 | 2 | 0 | <0.0001% |
| RICHSTONE ELLEN B | director | 10000 0.0105% | $6,995.00 | 1 | 0 | <0.0001% |
| O'Brien James Michael | Chief Financial Officer | 5000 0.0053% | $3,497.50 | 1 | 0 | <0.0001% |
$5,831,763 | 118 | -33.78% | $66.68M | |
$9,405,928 | 107 | 12.61% | $74.85M | |
$17,525,882 | 60 | 5.22% | $64.7M | |
$103,288,323 | 51 | 4.78% | $56.52M | |
$19,705,388 | 47 | 86.26% | $67.15M |
| Increased Positions | 32 | +41.56% | 3M | +13.47% |
| Decreased Positions | 24 | -31.17% | 3M | -13.31% |
| New Positions | 16 | New | 1M | New |
| Sold Out Positions | 8 | Sold Out | 1M | Sold Out |
| Total Postitions | 85 | +10.39% | 21M | +0.15% |
| Bios Capital Management, Lp | $8,820.00 | 6.82% | 6M | 0 | 0% | 2025-09-30 |
| Davenport & Co Llc | $3,953.00 | 3.06% | 2.69M | +3M | New | 2025-09-30 |
| Vanguard Group Inc | $3,942.00 | 3.05% | 2.68M | +1M | +105.59% | 2025-09-30 |
| Tang Capital Management Llc | $1,764.00 | 1.36% | 1.2M | +1M | New | 2025-09-30 |
| Chescapmanager Llc | $1,466.00 | 1.13% | 997,029 | +493,770 | +98.11% | 2025-09-30 |
| Blackrock, Inc. | $1,424.00 | 1.1% | 968,699 | +891,844 | +1,160.42% | 2025-09-30 |
| Jane Street Group, Llc | $1,361.00 | 1.05% | 926,150 | +912,936 | +6,908.85% | 2025-09-30 |
| Renaissance Technologies Llc | $1,049.00 | 0.81% | 713,500 | +617,100 | +640.14% | 2025-09-30 |
| Geode Capital Management, Llc | $1,048.00 | 0.81% | 712,727 | +344,007 | +93.3% | 2025-09-30 |
| Hilton Capital Management, Llc | $854.00 | 0.66% | 581,150 | +581,150 | New | 2025-09-30 |